Immunotherapy boost tested in fight against rectal cancer
NCT ID NCT03921684
Summary
This study is testing whether adding an immunotherapy drug called nivolumab to the standard pre-surgery treatment (chemotherapy and radiation) works better for people with locally advanced rectal cancer. The goal is to see if this combination helps eliminate more of the cancer before surgery, potentially improving long-term outcomes. The study will also closely monitor side effects to ensure the treatment is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel
Conditions
Explore the condition pages connected to this study.